Core Insights - Brii Biosciences Limited is advancing its hepatitis B virus (HBV) functional cure program through multiple Phase 2b trials, including ENRICH and ENHANCE studies, aiming for higher cure rates [2][5] - The company has entered a strategic collaboration with Joincare Pharmaceutical Group for the development of soralimixin in Greater China, enhancing its portfolio and partnership strategy [2][8] - Brii Bio maintains a strong cash position of US$289.9 million, sufficient to support its late-stage development plans and early discovery initiatives [3][13] HBV Program Updates - The ENSURE study shows that prior treatment with BRII-179 and elebsiran can induce robust anti-HBs responses, with 61% of patients achieving HBsAg seroclearance at Week 48 [6] - The company is assessing BRII-179 in two additional Phase 2b trials, ENRICH and ENHANCE, to identify optimal combination regimens for HBV treatment [12] - Data from the ongoing studies are expected to inform the next phase of the clinical strategy for HBV functional cure [9][12] Financial Performance - As of June 30, 2025, the company's cash and cash equivalents were RMB2,075.3 million, a decrease of 14.0% from the previous year, primarily due to R&D expenditures [13] - Research and development expenses for the first half of 2025 were RMB117.0 million, reflecting a decrease of 7.3% compared to the same period in 2024, indicating effective cost control measures [13][20] - Administrative expenses decreased by 26.0% to RMB58.2 million, attributed to reduced employee costs and facility-related expenses [20] Strategic Outlook - Brii Bio is committed to delivering innovative therapies for infectious diseases, with a focus on achieving a functional cure for HBV [9] - The company plans to continue expanding its internal discovery capabilities and partnerships to drive sustainable growth [4][10] - Key data readouts from the HBV functional cure program are expected in the first half of 2026, which will shape future clinical strategies [9]

Corporate Overview Presentation August 2025 2025 Vir Biotechnology, Inc. 1 Legal disclaimer Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: the therapeutic and commercial potential of Vir Biotechnology's CHD program, as well as Vir Biotechnology's strategy, plans and expectations related thereto; the therapeutic and commercial potential of V ...

Company Overview - Vir Biotechnology, Inc. (VIR) shares increased by 11.9% to close at $5.93, with trading volume significantly higher than usual, contrasting with a 2.2% loss over the past four weeks [1][2] Pipeline and Development - The rise in stock price is linked to positive investor sentiment regarding tobevibart, Vir Biotechnology's late-stage pipeline candidate, which is in a phase III ECLIPSE 1 study for chronic hepatitis delta (CHD) treatment [2] - The company is preparing to start a phase III ECLIPSE 2 study to evaluate the efficacy and safety of switching to tobevibart and elebsiran for CHD patients not achieving viral suppression with bulevirtide [2] Financial Expectations - The upcoming quarterly report is expected to show a loss of $0.74 per share, reflecting a year-over-year increase of 27.5%, while revenues are projected at $7.05 million, up 128.8% from the previous year [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Vir Biotechnology operates within the Zacks Medical - Biomedical and Genetics industry, which includes other companies like Opus Genetics, Inc. (IRD), that also has a Zacks Rank of 2 (Buy) [4][5]

Core Insights - The company announced the latest data from its ongoing ENSURE Phase 2 study at the 34th Asia-Pacific Association for the Study of the Liver meeting, highlighting the potential of elebsiran in treating chronic hepatitis B virus (HBV) infection [1][2] Group 1: Study Findings - The ENSURE study (NCT05970289) is a multi-center, open-label Phase 2 trial assessing the efficacy of elebsiran, a research small interfering RNA (siRNA), in combination with PEG-IFNα for chronic HBV patients with baseline HBsAg levels between 100-3,000 IU/mL [1] - In cohort 4, participants who previously responded to BRII-179 treatment showed a significantly higher HBsAg seroclearance rate of 55.6% (10/18) compared to 10.0% (1/10) in non-responders at week 24 [2][4] - The overall HBsAg seroclearance rate in cohort 4 was 39.3% (11/28) at week 24, indicating the potential of BRII-179 as a predictive tool for identifying patients likely to respond to curative therapies [2][4] Group 2: Treatment Efficacy - Participants receiving elebsiran in combination with PEG-IFNα had higher HBsAg seroclearance rates and seroconversion rates at the end of treatment (EOT) compared to those receiving PEG-IFNα alone [2][6] - At EOT, the HBsAg seroclearance rates for the elebsiran 200 mg and 100 mg plus PEG-IFNα groups were 26.3% (5/19) and 33.3% (6/18), respectively, significantly higher than the 5.6% in the PEG-IFNα monotherapy group [6] - The average HBsAg decline was greater in the elebsiran plus PEG-IFNα groups, with reductions of -2.47 and -3.01 log10 IU/mL compared to -1.02 log10 IU/mL in the PEG-IFNα group [6][7] Group 3: Expert Commentary - Professor Huang Lihong stated that the positive data from cohort 4 opens new avenues for functional cure in HBV, emphasizing BRII-179's role in identifying patients who can generate necessary HBsAg antibody responses [3] - Dr. David Margolis highlighted the encouraging results supporting the development of strategies to enrich target populations for chronic HBV functional cure, aiming to improve cure rates for the 254 million chronic HBV patients globally [3]